Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Title:
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Author:
Robert, Caroline Dummer, Reinhard Gutzmer, Ralf Lorigan, Paul Kim, Kevin B Nyakas, Marta Arance, Ana Liszkay, Gabriella Schadendorf, Dirk Cantarini, Mireille Spencer, Stuart Middleton, Mark R